Skip to content
Investors and analysts are invited to
attend a virtual investor presentation
and Q&A which will provide greater
understanding of our business and
outlook following the disposal of our
European Thrombosis Business.
Click to view our
Investor Day webcast

ABOUT ASPEN

 

Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, maximising the value we create for our business and our diverse stakeholders.

With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

09
December 2020
Virtual Annual General Meeting.

11
December 2020
2020 Virtual Investor Day

11
March 2021
2021 Interim Results on SENS

12
March 2021
J.P. Morgan South Africa Healthcare Forum - 2021 Interim Results presentation

09
September 2021
2021 Year End Results on SENS

10
September 2021
2021 Year End Results presentation

LATEST RESULTS

Aspen 2020 Integrated Report

Aspen 2020 Annual Financial Statements

Aspen 2020 Corporate Brochure

Aspen Group unaudited financial results for the year ended 30 June 2020

Aspen short form announcement year end results

Aspen year end results webcast

2020 Annual Results Presentation For the year ended 30 June 2020

Regional
Overviews

DEVELOPED EUROPE

SUB-SAHARAN AFRICA

AUSTRALASIA

LATIN AMERICA

DEVELOPING EUROPE & CIS

China

Other Asia

Middle East and North Africa

USA & Canada

DEVELOPED EUROPE

 

Sterile Focus Brands and third party manufacturing are the most material contributors to revenue in this region. The active pharmaceutical ingredient (“API”) site in The Netherlands, supported by its satellite operation at Sioux City, in the United States supplies APIs worldwide. We provide a broad range of sterile medicines in Europe largely utilised in an acute hospital setting.

Key countries
France
Germany
Italy
The Netherlands
United Kingdom
Number of products launched:
Nil
(2019: Nil)
 

The Developed Europe Injectable Thrombosis market was valued at EUR1,9 billion as at March 2020.

The EU5 (France, Germany, Italy, Spain, UK) propofol market was valued at EUR372 million as at 31 December 2019.

 

SUB-SAHARAN AFRICA

 

Within the Sub-Saharan Africa business local brands have strong brand equity and continue to contribute positively to Aspen’s leading presence in the South African market. We also supply OTC brands in various home markets outside South Africa, mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key countries
Botswana
Kenya
Namibia
South Africa
Tanzania

Number of products launched:
22
(2019: 22)

 

The South African private pharmaceutical sector was valued at R45,4 billion for the MAT period July 2020.

In South Africa, four out of the top 10 brands in the private sector were Aspen (and Ethicare) products.

 

Australasia

 

Australia is the third largest region by revenue contribution, supported by strong sales teams promoting a diversified portfolio of prescription, OTC and consumer health products. Aspen’s production facilities are also one of the largest manufacturing sites in Australia, with an ability to produce tablets, liquids and semi-solids.

Key countries
Australia
New Zealand

Number of products launched:
2
(2019: 4)

The Australian pharmaceutical sector was valued at USD13,2 billion as at MAT August 2020.

Aspen was ranked fourth by volume in the Australian pharmaceutical sector for the period ended 31 August 2020, and first among non-generic suppliers.

 

Latin America

 

Latin America includes a portfolio of locally recognised and trusted brands sold across the public and private sector. Brazil and Mexico are the biggest contributors to regional performance.

Key countries
Brazil
Chile
Colombia
Ecuador
Mexico

Number of products launched:
6
(2019: 8)#

The Brazilian private pharmaceutical market declined 3%, negatively impacted by foreign exchange movements and was valued by IQVIA at USD26 billion, while the Brazilian pharmaceutical market in local currency grew 11% for the year 30 June 2020.

 

Developing Europe & CIS

 

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Brands, followed by Regional Brands which are OTC and prescription.

Key countries
Czech Republic
Poland
Romania
Russia
Slovakia
Number of products launched:
Nil
(2019: Nil)
 

The Developing Europe & CIS Injectable thrombosis market was valued at EUR318 million as at March 2020.

 

China

 

Aspen China offers a select portfolio of products with which Aspen can effectively compete. China’s revenue is largely from Sterile Focus Brands, offering products which are both niche and aligned with market trends in the region.

 
Number of products launched:

Nil
(2019: Nil)
 

Propofol market sales declined 4% to RMB3.6 billion MAT May 2020.

Ropivacaine in China contracted 1% to RMB633 million in MAT May 2020.

 

Other Asia

 

Australia is the third largest region by revenue contribution, supported by strong sales teams promoting a diversified portfolio of prescription, OTC and consumer health products. Aspen’s production facilities are also one of the largest manufacturing sites in Australia, with an ability to produce tablets, liquids and semi-solids.

Key countries
Hong Kong
Philippines
Singapore
Taiwan

Number of products launched:
1
(2019: 4)

The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.

The Indonesian pharmaceutical market is forecast to grow at a CAGR of 2% between 2019 and 2024, reaching Rp87,578 billion by 2024.

 

Middle East and North Africa

 

The region supplies products with international brand equity, as well as regionally recognised medicines which are supplied across multiple territories within Middle East and North Africa (“MENA”).

Key countries
Algeria
Egypt
Morocco
Saudi Arabia
Turkey
United Arab Emirates

Number of products launched:
7
(2019: 7)

MENA growth will be mainly driven by Egypt and Turkey over the next three years.

The MENA region is expected to grow in USD by value at 4.6% p.a. four-year CAGR between 2019 and 2023. The largest markets are expected to be Turkey, Saudi Arabia, Egypt, Algeria, UAE and Morocco.

 

USA & Canada

 

Aspen USA & Canada revenues are almost equally split in Anaesthetics and Regional Brands. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.

Key countries
Canada
USA

Number of products launched:
1
(2019: Nil)

 

Scroll To Top